Biotech Investment
Funding rounds, deals, M&A and the money moving the sector.
Latest Biotech Investment news
Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News
Read at Barchart.com →Watertown biotech agrees to reverse merger with Vivek Ramaswamy-backed startup
Read at The Business Journals →Chronic pain biotech co-founded by Vivek Ramaswamy joins reverse merger train
Read at Endpoints News →Israel Englander's HOWL Stock Soars on $500M Deal - Werewolf Therapeutics (NASDAQ:HOWL)
Read at Benzinga →Lepu ScienTech Plans RMB1.09 Billion Connected Acquisition in Biotech Arm
Read at TipRanks →Beyond biology: Nanobiotix's physics-first approach to cancer｜Beyond Biotech
Read at finance.biggo.com →From the knowledge base
What did we learn from Big Pharma’s Q2 results?
Fierce editors break down Big Pharma’s second-quarter results, from AI and new leadership to the oral GLP-1 race and potential new blockbusters.
Regulatory tracker: J&J scores EU approval for Tecvayli-Darzalex combo
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.
The Oral GLP-1 Tracker: Novo's Wegovy pill back on track as Lilly's momentum slows
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions.
Lundbeck continues neuroscience evolution as CEO keeps company ‘punching above its weight’
Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove its mettle as a “neuroscience challenger” capable of “punching above its weight.”
Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’
Boehringer Ingelheim has suspended a phase 1 trial of an investigational small molecule drug while it seeks to understand a “safety event,” although the German pharma isn't shedding light on the nature of the incident for now.
Why Pheast’s CEO has no regrets about transparent approach to R&D despite competitors circling
Pheast Therapeutics may have learned the hard way about the risks of competitors getting a glimpse of your heard-earned discoveries, but the immuno-oncology startup is so far sticking to its transparent approach.